INTRODUCTION
The catalogue of known genomic alterations in the cancer genome has been vastly enriched by the completion of large-scale projects of genome sequencing such as The Cancer Genome Atlas (TCGA) that analysed cancer genomes from more than 11 000 patients with 33 different cancer types and allowed the construction of comprehensive maps of the complex molecular landscape of cancer [1] .
Among the numerous studies that stemmed from the analysis of these large repositories of cancer genome data, there is a seminal work by the Wellcome Trust Sanger Institute that led to somehow unexpected results: the identification of distinct patterns of somatic mutations (referred to as 'mutational signatures') representing the marks of specific mutational processes that have modified the genome during the lifetime of an individual and left their 'imprint' in the cancer genome [2] . Such study focused its attention on all base substitutions, not only on the rare driver mutations, and hypothesized that the catalogue of mutations observed in a given cancer is the result of multiple mutational processes operative, generally at different times, during its evolution. The extraction of distinct mutational signatures was achieved by applying particular mathematical methods previously utilized to extract, for example, features from images to allow facial recognition.
A few studies have shown that, in addition to mutational marks, some exposures may also leave marks on the epigenome and in particular on the methylome, that is the levels of DNA methylation across the genome [3,4
In this article, we critically review recent findings on mutational and epigenetic signatures in cancer genomes with a particular focus on signatures potentially linked to the external environment and lifestyle.
MUTATIONAL SIGNATURES AND CANCER

The mutational signature framework
Most studies on mutational signatures focused only on base substitutions. As there are six possible base substitutions (C>A, C>T, C>G, T>A, T>C and T>G) and 16 sequence contexts (four possible bases at the 5 and 3 side of the mutated base) substitutions are classified into 96 types. The mutational catalogue (or spectrum) of a cancer genome is therefore seen as a probability distribution of these 96 types (Fig. 1a) .
As the mutational catalogue of a given tumour results from the combination of all the mutational processes operative during lifetime, it has been attempted to unveil its determinants by decomposing it into a (weighted) sum of simpler mutational signatures, each corresponding to a specific mutational process (Fig. 1b) . The weight is larger if the mutational process has a larger role in the final catalogue of mutations (Fig. 1c) : for example for exposures to mutagens that last longer and/or are more intense.
Different mathematical methods and computational tools have been proposed to properly identify mutational signatures and estimate the number of mutations each signature contributes to each catalogue. The first seminal articles that introduced the concept and framework to study mutational signatures [6, 8] and some of the more recent articles describing methods to extract signatures and tools for analysis are based on nonnegative matrix factorization, a decomposition algorithm similar to principal component analysis [9, 10] . Other methods are based on probabilistic models [11] [12] [13] or other kinds of decomposition methods [7] . A recent article critically reviews all existing algorithms and tools [14 & ]. All methods have been implemented in open-source packages freely available.
It is important to note that the identification of mutational signatures from cancer genomes is essentially a classification problem for which there is no guarantee of finding the underlying truth because of its unsupervised learning nature [ 
KEY POINTS
At least 30 patterns of mutations (referred to as 'mutational signatures') have been found in the cancer genome. They are the marks left on the cancer genome by the activity of specific mutational processes.
The mutational profile (often referred to as 'catalogue') of a given cancer is the combination of multiple signatures and depends on the intensity, timing and type of the mutational processes that occurred during its evolution.
The causes of most mutational signatures are still unknown, but some have been linked to the action of endogenous processes (e.g. the activity of APOBEC cytidine deaminases or defective DNA repair) or environmental exposures (e.g. tobacco smoke, ultraviolet light, aflatoxins, aristolochic acid and ionizing radiation).
The study of mutational signatures is providing useful insights to identify the causes of cancer, including exposures in specific groups of individuals (e.g. environmental carcinogens present in distinct geographical areas).
Tobacco-related DNA methylation alterations at specific CpG sites (mostly hypomethylated in smokers) are observed both in normal and cancer tissue for organs such as the lungs and others. associated with specific endogenous causes including mutations promoted by spontaneous deamination of 5-methylcytosine (signature 1 that correlates with age at cancer diagnosis), the overactivity of DNA editing by APOBEC cytidine deaminases (signatures 2 and 13), defective DNA repair (signatures 6, 15, 20 and 26) and defective repair of DNA doublestrand break by homologous recombination (signature 3 found in tumours linked to BRCA1 and BRCA2 mutations). Other signatures have been linked to exogenous causes and these are discussed in detail in the next section.
The exogenous causes of mutational signatures
The notion that exposure to ultraviolet (UV) radiation caused predominantly the transition cytosine to thymine (C>T) and tobacco smoke predominantly caused the transversion cytosine to adenine (C>A) has been established experimentally several decades ago [17] , well before the development of sequencing technologies. The idea that carcinogens leave fingerprints is, therefore, not novel [18] but the availability of data on a large number of cancer exomes or whole genomes and the development of appropriate mathematical methods greatly improved the capacity to identify such fingerprints [15 && ]. Although initially some of the mutational signatures have been linked to specific factors only on the basis of biological prior knowledge of their mutational effects [2] , more recently experimental studies and studies with information about environmental exposures and lifestyle are providing useful information to establish the causes of some signatures. Relative burden of each signature is given in (c). The decomposition was realized using the R package deconstructSigs [7] that decomposes a catalogue according to user-specified signatures. The unknown component accounting for the noise is relatively important for this sample. Note that the scale of the probability axis for signature 2 is different from the others: for illustration purposes, we zoomed in on the other plots.
To investigate mutational signatures in tobaccorelated cancers, Alexandrov et al. studied the cancer genomes from 2490 smokers and 1063 never smokers. For each cancer, they extracted the mutational signatures and estimated their contributions to the complete mutational catalogue [4 && ]. By comparing the estimated contributions in smokers and nonsmokers, they found that signatures corresponding to signatures 2,4,5,13,16 in COSMIC were more prevalent in smokers compared with nonsmokers. The study found that signature 4 is a strong signature of exposure to tobacco smoke with a higher prevalence in smokers than in nonsmokers for lung squamous cell carcinomas, lung adenocarcinomas, larynx and liver cancers. Signature 4 correlated with pack-years smoked and was also found in other cancers associated with cigarette smoking. Signature 4 was not found in tumour tissues from organs not directly exposed to tobacco smoke. Notably, signature 4 is characterized mostly by C>A transversions, an observation consistent with previous knowledge about the mutagenic effects of tobacco smoke, and its mutation profile is very close to that caused by exposure to some carcinogens present in tobacco smoke such as benzo[a]pyrene known from earlier experimental studies [19] .
Exposure to aflatoxin B1 (AFB1), a common contaminant in a variety of foods such as peanuts, corn and grains, is a major public health problem in some regions of Africa and Asia as it strongly increases the risk of hepatocellular carcinoma (HCC), especially when associated with hepatitis B. An innovative study that initially analysed mutational signatures from experimental models (human cell lines and liver cancers in mice exposed to AFB1) and then complemented the results with analyses of signatures extracted from human HCC genomes from a geographical region in which exposure to AFB1 is well documented, provided strong support to the likely link between exposure to AFB1 and signature 24 [20 && ]. Signature 24 has been found only in the genome of HCCs.
Another interesting application of mutational signatures is the study of the tumourigenic effect of ionizing radiation, particularly in the context of the iatrogenic effects of cancer treatment. Analyses of the genome of 12-s malignancies associated with radiation treatment of primary tumours identified two genomic imprints or signatures not present in cancers not exposed to ionizing radiation [21] . These signatures, being characterized by small deletions occurring with similar density across the genome as well as by balanced inversions, are not captured by the common methods based on base substitutions. To overcome the scarcity of genomic sequences for radiotherapy-induced cancers, it was proposed to conduct combined analyses of mutational catalogues from ionizing radiation-induced cancers in human and mice models [22 & ]. This type of analysis identified two signatures linked to ionizing radiation that had not been previously identified and may represent an useful approach also for other exposures.
The typical C>T transitions induced by exposing experimental systems to UV light, are characteristic of signature 7 that is found in melanomas and head and neck cancers. These observations have led to propose UV light as the cause of signature 7 [2] .
Aristolochic acid is a natural compound contained in plants from the Aristolochiaceae family used in some herbal remedies or traditional medicines. Aristolochic acid is a known nephrotoxic phytochemical and a carcinogen that was previously associated with urothelial cancers of the upper urinary tract. A study based on urothelial tumours from 15 patients with endemic nephropathy found signature 22 and linked it to aristolochic acid exposure [23] . Another important aspect of this study is that it demonstrates that such signature can be observed with exome sequencing of DNA from formalin-fixed paraffin-embedded tumour samples even at low sequencing coverage (less than 10Â). Signature 22 is mostly characterized by A>T and T>A transversions that were found in experimental studies based on human renal cells exposed to aristolochic acid [24] and in a series of urothelial cancers in patients with a documented exposure to aristolochic acid [25] . Evidence of exposure to aristolochic acid was found in the genomes of four of 110 bladder cancers from Singapore and China [26] and, interestingly, in 11 of 93 HCCs, a type of cancer not known to be associated with exposure to aristolochic acid [24] . The presence of the aristolochic-acidrelated signature was found also in clear cell renal cell carcinomas [27, 28] with a particularly high prevalence in cases from Romania [29] . These studies do not refer explicitly to specific COSMIC signatures but their results are consistent with the proposed link between COSMIC signature 22 and exposure to aristolochic acid.
EXPOSURE-RELATED EPIGENETIC SIGNATURES IN THE METHYLOME OF TUMOUR TISSUE
DNA methylation is an epigenetic mechanism consisting in the addition of a methyl group to the cytosine base of the CpG nucleotides of the DNA sequence. DNA methylation modulates gene expression by influencing DNA transcription and it is involved in many biological processes, including the response of cells to external stress. Modifications of physiologic DNA methylation patterns are associated with the development of many diseases, including cancer for which altered DNA methylation has been observed in early stages of carcinogenesis and for many cancer types [30] . Features common to many cancer tissues are global hypomethylation, causing genome instability [31] , and hypomethylation or hypermethylation of specific loci, causing overexpression of oncogenes and underexpression of tumour suppression genes. Many studies have been conducted to identify methylation signatures of risk (primary prevention) or early presence of disease (secondary prevention), with the support of a variety of molecular techniques able to profile whole genome methylation or identify differentially methylated regions [32 & ]. Of particular interest are the studies that established a relationship between some environmental and lifestyle factors and in particular cigarette smoking and levels of methylation in DNA from blood: altered methylation levels in thousands of CpG sites have been found to be associated with smoking and smoking duration and intensity [33,34 & ]. In case-control studies nested within prospective cohorts, some of these alterations have been found to be associated with lung-cancer risk even after adjustment for reported history of cigarette smoking [35 && ,36]. The study conducted by Alexandrov et al. [4 && ] that scrutinized tobacco-related mutational signatures in 5243 tobacco-related cancers, also reported the results of analyses of tobacco-related methylation signatures in tumour DNA. Average differences in DNA methylation larger than 5% between smokers and lifelong-nonsmokers were observed in tumor tissue of lung adenocarcinomas cases and oral cancer cases, but not in tumor tissues of other smokingrelated cancer types. The main differences were observed for lung adenocarcinomas in which in smokers 369 CpGs were hypomethylated and 65 hypermethylated; for oral cancer, only eight differentially methylated CpGs were observed, five of whom were hypomethylated. Significantly, none of these CpGs are among those found to be differentially methylated in blood or buccal cells of smokers and nonsmokers.
A DNA methylation-based index associated with exposure to cigarette smoking was developed from 1501 differentially methylated CpGs in epithelial buccal cells of smokers and nonsmokers [3] . Using methylome data for normal and cancer tissue and comparing the estimated index, it was found to be extremely accurate in discriminating between normal and cancer tissue for lung cancer and other cancer types; the index was also able to discriminate between lung lesions that regressed from those that progressed.
Stueve et al. searched for methylation signatures associated with tobacco smoke in nontumor lung tissue (NTL) from 237 lung-cancer cases using the Infinium HumanMethylation450 BeadChip array and identified seven CpGs in which hypomethylation was associated with cigarette smoking [5 & ]. For all these CpGs, the association between hypomethylation and cigarette smoking was also found in TCGA methylation data concerning NTL tissue. Five of the seven CpGs corresponded to CpGs for which tobacco-related hypomethylation had been previously observed in DNA from peripheral blood. Notably, for the cg05575921 locus, an association between hypomethylation and lung-cancer risk independent of the exposure to tobacco smoke had been previously reported [35 && ,36] . In an analysis using a line of epithelial cells exposed to cigarette smoke condensate (CSC) aimed at understanding the possible functional consequences of hypomethylation at the identified CpGs, induced gene expression was evaluated in the 1-Mb window flanking the CpGs [5 & ]. Hypomethylation levels in four CpGs were associated with induced expression of the genes AHRR, CYP1B1, ENTPD2 in the CSCexposed cell line. Such observation, confirmed in the TCGA NTL data, is particularly interesting as in the promoters of the AHRR, CYP1B1 and ENTPD2 genes are present binding sites for the aryl hydrocarbon receptor, a transcription factor involved in detoxification and bioactivation of procarcinogens in tobacco smoke, suggesting a possible pathway linking smoking induced methylation to lung cancer. Significantly, in addition to the observed association with tobacco-induced hypomethylation at specific loci, Stueve et al. noticed that increased expression of the AHRR and, to a lesser extent, CYP1B1 genes was also associated with the tobacco-related C>A substitutions.
CONCLUSION
Cancer genomes and epigenomes contain traces of past events, including the action of exposures to environmental factors. The mutational profile of a cancer genome results from the linear superposition of all the traces, or signatures, left by mutational processes. Identifying the former and estimating their contribution to a given cancer genome thus requires extraction of signatures from the observed spectrum of mutations as well as their careful validation and interpretation. Several algorithms for signature extraction from cancer genomes are available, but they should be utilized with care as the signatures extracted with different methods may not be directly comparable. Further work is needed for the validation and comparison of available methods. In addition, the development of new appropriate methodology, both in terms of study design and statistical tools is likely to be needed as most exposures may not have a unique signature but rather correspond to a combination of existing (i.e. already observed) and possibly new signatures that are difficult to detect.
Recent studies have demonstrated the existence of cancer epigenetic signatures related to exposures. It is a promising area but still in its infancy as it has been mainly limited to one epigenetic mark (i.e. DNA methylation) and to exposure to cigarette smoking. Further progress in this area may require the development of specific analytical methods and tools as the nature of epigenetic and genomic data are different (e.g. DNA methylation is a continuous variable).
The analysis of mutational and epigenetic signatures in the context of experimental studies as well as in epidemiological studies with access to tumour tissue may greatly help to interpret signatures and link them to specific causes.
